Publications
December 6, 2022
Poster 159P: COM701 in combination with nivolumab demonstrates preliminary antitumor activity in patients with platinum resistant epithelial ovarian cancer
Yeku O et al, ESMO-IO 2022
December 6, 2022
Poster 130P: COM701 ± nivolumab – preliminary results of antitumor activity from a Phase 1 study in patients with metastatic NSCLC who have received prior PD-1/PD-L1 inhibitor
Sullivan R et al, ESMO-IO 2022
December 6, 2022
Poster 158P: Triple blockade of the DNAM-axis with COM701 + BMS-986207 + nivolumab demonstrates preliminary antitumor activity in patients with platinum resistant OVCA
Moroney J.W. et al, ESMO-IO 2022
December 1, 2022
Abstract 420: Triple blockade of the DNAM-axis with COM701 + BMS-986207 + nivolumab demonstrates preliminary antitumor activity in patients with platinum resistant OVCA
Moroney J et al, ESMO-IO 2022
December 1, 2022
Abstract 338: COM701 in combination with nivolumab demonstrates preliminary antitumor activity in patients with platinum resistant epithelial ovarian cancer
Yeku O et al, ESMO-IO 2022
December 1, 2022
Abstract 306: COM701 ± nivolumab – preliminary results of antitumor activity from a Phase 1 study in patients with metastatic NSCLC who have received prior PD-1/PD-L1 inhibitor
Sullivan R et al, ESMO-IO 2022
November 10, 2022
Poster: COM701 plus nivolumab demonstrates preliminary antitumor activity and immune modulation of tumor microenvironment in patients with metastatic MSS-CRC and liver metastases.
Overman, M, J et al, SITC 2022
November 10, 2022
Presentation: COM701 plus nivolumab demonstrates preliminary antitumor activity and immune modulation of tumor microenvironment in patients with metastatic MSS-CRC and liver metastases.
Overman, M, J et al, SITC 2022
November 10, 2022
Abstract: COM701 plus nivolumab demonstrates preliminary antitumor activity and immune modulation of tumor microenvironment in patients with metastatic MSS-CRC and liver metastases.
Overman, M, J et al, SITC 2022
November 12, 2021
COM701 in combination with BMS-986207 (anti-TIGIT antibody) and nivolumab – preliminary results of safety, tolerability and pharmacokinetics in patients with advanced solid tumors
Ecaterina Elena Dumbrava, et al, SITC 2021 annual meeting
